302.46
-1.54 (-0.51%)
| Previous Close | 304.00 |
| Open | 303.81 |
| Volume | 489,575 |
| Avg. Volume (3M) | 1,039,669 |
| Market Cap | 39,637,987,328 |
| Price / Earnings (Forward) | 10.00 |
| Price / Sales | 16.95 |
| Price / Book | 349.85 |
| 52 Weeks Range | |
| Earnings Date | 30 Jul 2025 - 4 Aug 2025 |
| Profit Margin | -11.49% |
| Operating Margin (TTM) | 3.04% |
| Diluted EPS (TTM) | -2.11 |
| Quarterly Revenue Growth (YOY) | 20.20% |
| Total Debt/Equity (MRQ) | 2,358.25% |
| Current Ratio (MRQ) | 3.04 |
| Operating Cash Flow (TTM) | -45.11 M |
| Levered Free Cash Flow (TTM) | 223.09 M |
| Return on Assets (TTM) | -1.79% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Alnylam Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.63 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Mid Core |
| % Held by Insiders | 3.83% |
| % Held by Institutions | 97.49% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 500.00 (HC Wainwright & Co., 65.31%) | Buy |
| Median | 345.00 (14.07%) | |
| Low | 268.00 (Morgan Stanley, -11.39%) | Hold |
| Average | 353.64 (16.92%) | |
| Total | 9 Buy, 2 Hold | |
| Avg. Price @ Call | 250.68 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Wells Fargo | 30 Jun 2025 | 333.00 (10.10%) | Hold | 0.000 |
| Needham | 26 Jun 2025 | 377.00 (24.64%) | Buy | 309.70 |
| 09 Apr 2025 | 320.00 (5.80%) | Buy | 243.27 | |
| BMO Capital | 24 Jun 2025 | 360.00 (19.02%) | Buy | 309.70 |
| JP Morgan | 12 Jun 2025 | 338.00 (11.75%) | Buy | 304.67 |
| Chardan Capital | 02 May 2025 | 325.00 (7.45%) | Buy | 259.39 |
| UBS | 02 May 2025 | 349.00 (15.39%) | Buy | 259.39 |
| Morgan Stanley | 11 Apr 2025 | 268.00 (-11.39%) | Hold | 237.77 |
| HC Wainwright & Co. | 02 Apr 2025 | 500.00 (65.31%) | Buy | 266.83 |
| Redburn Atlantic | 31 Mar 2025 | 353.00 (16.71%) | Buy | 270.02 |
| Scotiabank | 31 Mar 2025 | 342.00 (13.07%) | Buy | 270.02 |
| Stifel | 31 Mar 2025 | 345.00 (14.06%) | Buy | 270.02 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |